Extracellular Matrix Dermatopontin Modulates Prostate Cell Growth in Vivo

Androgen inhibits the growth of carcinoma cell lines established from prostate cancer xenografts that escape androgen treatment

“…However, we cannot definitely exclude that androgen modified the fibroblast cell growth in co-culture In addition, it remains possible that key components were missing from the matrix used, e.g. the extra-cellular matrix dermatopontin that modulates prostate cell growth in vivo [22]. Other stroma cells, such as macrophages [23], lymphocytes or endothelial cells might also be the true partners of carcinoma cells in the tumors.…”

Identification of PDE4D as a Proliferation Promoting Factor in Prostate Cancer Using a Sleeping Beauty Transposon-Based Somatic Mutagenesis Screen

“…In addition to Pde4d , this study identified 18 other genes as candidate prostate cancer genes including genes at CISs in the prostate data set (Supplemental Table 1), genes at CISs for the combined prostate + RTCGD data sets (Supplemental Table 2), and prostate insertions at genes that had previously been identified as CISs (Supplemental Table 3). Among the 19 candidate prostate cancer genes identified in our study were 5 genes that have previously been investigated for their potential roles in prostate cancer including Dpt, Notch1, Runx3, Igf1r , and Ghr [representative studies: (45–49)]. The remaining 14 candidate prostate cancer genes have not previously been investigated for their potential roles in prostate cancer.…”

The composition of prostate core matrisome in vivo and in vitro unveiled by mass spectrometric analysis

“…Furthermore, dermatopontin may enhance cell adhesion mediated by α3β1 integrin . In a transgenic mouse model, dermatopontin promotes the formation of intra‐epithelial neoplasia in prostate . Lumican is a small leucine‐rich proteoglycan (SLRP), recently reported to play a restrictive role on primary prostate cancer progression .…”

“…[37][38][39] In a transgenic mouse model, dermatopontin promotes the formation of intra-epithelial neoplasia in prostate. 40 Lumican is a small leucine-rich proteoglycan (SLRP), recently reported to play a restrictive role on primary prostate cancer progression. 41 Another SLRP, osteoglycin, is also a regulator of collagen fibrillogenesis and its expression is often decreased in malignant tumors including prostate cancer.…”